Right prescription

The e-commerce group is injecting assets into a healthcare subsidiary, now worth a punchy $25 bln. It’s a bet that the coronavirus will accelerate reforms, like opening China’s $370 bln drug industry to web retailers. Alibaba’s scale could deliver a potent treatment to investors.